Gilead (GILD) CEO says Epclusa list price will be $74,760 for 12 weeks - Bloomberg

June 28, 2016 11:06 AM EDT

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Gilead (Nasdaq: GILD) CEO John Milligan says Epclusa list price will be $74,760 for 12 weeks, according to Bloomberg.

UPDATE - News follows the FDA Approval of Epclusa in all hepatits C genotypes, which was announced on Tuesday morning.

Notably, Epclusa's list price is lower than $84,000 for Sovaldi and $94,500 for a Harvoni treatment.

Mulligan note that Epclusa's holds the best price for the system and the company.

Shares of Gilead are up 4 percent Tuesday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Management Comments, Trader Talk